Clinical trial · Interventional
Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
A Randomised Study Comparing an Oral Regimen (Idarubicin and Etoposide) With an Intravenous Regimen (MAE) for Consolidation in Patients Over 55 Years With Acute Myeloid Leukaemia in First Complete Remission
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating older patients with acute myeloid leukemia. PURPOSE: Randomized phase III trial to compare the effectiveness of two different combination chemotherapy regimens in treating older patients with acute myeloid leukemia in first remission.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cytarabine | Drug | Cytarabine | ALIAS |
| etoposide | Drug | Etoposide | ALIAS |
| idarubicin | Drug | Idarubicin | ALIAS |
| mitoxantrone hydrochloride | Drug | Mitoxantrone | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 55 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed de novo or secondary acute myeloid leukemia (AML) * Prior myelodysplasia allowed * Refractory anemia with excess blasts (RAEB) OR * RAEB in transformation * No relapsed AML * No chronic granulocytic leukemia in transformation * No CNS disease PATIENT CHARACTERISTICS: Age: * Over 55 Performance status: * Not specified Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * Bilirubin no greater than 1.5 times upper limit of normal (ULN) * Transaminases no greater than 2.5 times ULN Renal: * Creatinine no greater than 2.5 times ULN Cardiovascular: * No severe or uncontrolled cardiac failure Other: * No serious medical, social, or psychological condition * Not HIV 1 or 2 seropositive PRIOR CONCURRENT THERAPY: Biologic therapy: * No plan for future autograft Chemotherapy: * No prior chemotherapy for myelodysplastic syndrome or AML Endocrine therapy: * Not specifed Radiotherapy: * Not specified Surgery: * Not specified Other: * No concurrent aluminum or magnesium-based antacids
References
Publications (0)
Data not yet available